Jan, 2006

U.S.A.
News / Therapeutic Area News
Astellas Educates and Informs Physicians and Patients on Changes to Protopic Label in the US
Recently, new information was added to the US labeling for the class of topical calcineurin inhibitors, or TCIs, which includes Protopic® (tacrolimus) Ointment and pimecrolimus cream. The new...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Net U.S. Tarceva(R) Sales for Fourth Quarter and Year-End 2005; Narrows Macugen(R) Guidance & Updates Cash Position on Balance Sheet
MELVILLE, N.Y., Jan 11, 2006 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter and year-end net U.S. sales for its flagship product, Tarceva® (erlotinib)....
Read More

Dec, 2005

U.S.A.
News / Therapeutic Area News
FDA Approves Astellas' Vaprisol® for the Treatment of Euvolemic Hyponatremia
DEERFIELD, Illinois, December 30 — Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VAPRISOL® (investigational name: YM087, generic name:...
Read More

Nov, 2005

U.S.A.
News / Therapeutic Area News
Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections
SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, 2005 -- Theravance, Inc., and Astellas Pharma Inc. announced today that they have entered into a collaboration for the development and...
Read More
U.S.A.
News / Therapeutic Area News
Multimedia News Release -- FDA Approves Tarceva(R) in Combination With Gemcitabine Chemotherapy for Treatment of Locally Advanced, Inoperable or Metastatic Pancreatic Cancer
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and...
Read More